Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
Authors:
- Eduard ParelladaEPEduard Parellada
- Filippos KouniakisFKFilippos Kouniakis
- Aldona SiurkuteASAldona Siurkute
- Andreas SchreinerASAndreas Schreiner
- Liana DonLDLiana Don
- 1 May 2010
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 25 (3) , 149-154
Abstract
This postauthorization safety study evaluated the long-term safety, tolerability, and efficacy of risperidone long-acting injectable (RLAI) in routine clinical practice. In this 6-month, multicenter, European, naturalistic study, patients were included if, during routine clinical practice, long-term antipsychotic therapy with RLAI was deemed necessary by the treating physician. Efficacy measures included Clinical Global Impression-Severity and Global Assessment of Functioning. Safety was evaluated by recording treatment-emergent adverse events (AE). RLAI was initiated in 5134 patients (aged 14-94 years); predominantly male (58.6%) with paranoid schizophrenia (69.8%). RLAI initial doses were 25 mg every 2 weeks (37.0% patients), 37.5 mg (18.0%), and 50 mg (44.4%). Treatment was completed by 4314 patients (84.0%). RLAI was discontinued on account of loss to follow-up (n=346; 6.7%), insufficient response (n=116; 2.3%), and AEs (n=106; 2.1%). Clinical Global Impression-Severity significantly improved from baseline to endpoint (P or = 5% of patients were akathisia, extrapyramidal disorders, depression, psychotic disorder, anxiety, and weight gain. Serious AEs were reported by 384 (8%) patients. This study confirms good safety, tolerability, and efficacy with RLAI in routine clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Tardive dyskinesia and new antipsychoticsCurrent Opinion in Psychiatry, 2008
- A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophreniaEuropean Neuropsychopharmacology, 2007
- Generalizability of cancer clinical trial resultsCancer, 2006
- Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)The Journal of Clinical Psychiatry, 2006
- Clinical Trial Participants Compared with Nonparticipants in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) studyInternational Clinical Psychopharmacology, 2005
- Differences between participants and nonparticipants in an exercise trial for adults with rheumatoid arthritisArthritis Care & Research, 2004
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- Treatment of Schizophrenia With Long-Acting Injectable RisperidoneThe Journal of Clinical Psychiatry, 2003
- Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical AntipsychoticAmerican Journal of Psychiatry, 2003